SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neuroscience
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scott_jiminez who wrote (183)3/11/2001 3:57:31 PM
From: NeuroInvestment  Read Replies (2) of 278
 
A veritable bounty of bombast. Unfortunately, Post 183 completely disregards the issues raised in 182, in response to the statement that: "the concept of neurological replacement therapy, whether based on cellular augmentation, growth factor supplementation, etc. is bound to not simply fail...but to initiate a cascade of unintended side effects with tragic consequences for (largely) unsuspecting patients." Instead, the reply focused upon efficacy (a worthy but separate topic, one which should also involve discussions of placebo/reverse placebo effects, and the wisdom of using a population, wherein Parkinsonian dementia is prevalent, as their own symptom raters over time) and considerable sanctimony. Perhaps we will just have to wait with great anticipation for the promised "balanced history of this procedure in the near future."

NeuroInvestment (www.neuroinvestment.com)
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News